TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Peak sacral interface pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CPAP compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: headache NRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rate of manipulation treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 physical component summary score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: pain scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: endothelial integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of fields with displacements of < or = 5.0 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of fields with rotations of < or = 2.0 degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10% increase in rectal volume receiving at least 60 Gy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropathic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Straight leg raise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe swelling (≥ grade 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severely retracted eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate at 9 and 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ADAS-cog scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients demonstrating treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improvements in anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in general psychological profile and functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal obstruction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: established diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: FIM Total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost savings in nursing staff dollars
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oxidative stress (serum MDA, SOD, TAC levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: metabolic equivalents (MET) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for rescue medication for sedation
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of laboratory-confirmed influenza infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Access to care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: BPRS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASAS‐NSAID score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity index of dyspepsia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean biofilm percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Explantation rate
Endpoint domain: Adverse events/effects
Primary endpoint: aerobic capacity (VO2 max·kg -1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal external output (Wmax·kg -1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microaspiration of gastric contents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (QALY)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bioavailability of isavuconazole (AUC∞ and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum 25OHD3 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alterations in platelet protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: live-birth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Left ventricular end-systolic diameter (LVESD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of voids/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incontinence episodes/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pulse Wave Velocity (PWV) in elastic arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3-year bRFS
Endpoint domain: Mortality/survival
Primary endpoint: Impotence rates
Endpoint domain: Adverse events/effects
Primary endpoint: Overall analgesic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (nausea, vomiting, dizziness)
Endpoint domain: Adverse events/effects
Primary endpoint: Completion time for fiberoptic orotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global rating scale evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in skin pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in skin roughness and wrinkling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increased density of dermal collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Self ratings of anxiety and tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg-extension strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days with sore throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise oxygen consumption (exercise VO(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cycle ergometer time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOMA-R improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum leptin levels decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum hsCRP levels decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Net clinical benefit (death, myocardial infarction, stroke, major bleeding)
Endpoint domain: Mortality/survival
Primary endpoint: Mean ACO score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fibrotic PCO score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean capsulorhexis area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of all the pill rules
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in particle exposures (PEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaginal-cuff relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: intraprocedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a ≥20% improvement in the 6 min walk test and a ≥15% score increase on the Kansas City Cardiomyopathy Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abolition of venous reflux and occlusion of the vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Symptoms and QOL improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximal detrusor pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete continence after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean weight gain during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective reports of somnolence
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Quantitative EEG power increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to repeat UDS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 9-HPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dexterity-related ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: average drinks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average drinking days per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum consumption on 1 day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disablement rate
Endpoint domain: Mortality/survival
Primary endpoint: nerve defect score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: LP(a) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hematological toxicity (leukopenia and thrombocytopenia)
Endpoint domain: Adverse events/effects
Primary endpoint: Humidity of inspired gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature of inspired gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time-to-progression (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of next needed HPV vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU stay (hours)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: requirement for noninvasive ventilation (hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in sitosterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in campesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knowledge about anatomy and fertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy to communicate with a partner
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Planning for protected sex and avoiding unprotected sex
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of exclusive breastfeeding (EBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention bias scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of selection of low- and moderate-fat entrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Airway pressure (Ppeak, Pplat) and airway resistance (Raw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cerebral Blood Flow (CBF) at 5 minutes postadministration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hospitalizations for asthma
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of unscheduled asthma-related outpatient visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of asthma-related emergency room visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Post-operative PPSS and Riker SAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Pleth Index (SPI) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bispectral Index (BIS) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of Graves' disease
Endpoint domain: Mortality/survival
Primary endpoint: differential count of eosinophils in the peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: scores in all the domains of the AQLQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incidence of occiput posterior position at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Urine flow measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decrease in plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in S. mutans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiopulmonary exercise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma free choline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leukocyte acetylcholine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Beta-hydroxybutyrate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pain during the biopsy portion of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum alkaline phosphatase (AP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary 24‐h‐hydroxyprolin excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean low back pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Academic productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Work self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average hours worked per week
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 30-day composite rate of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Infarct size assessed by cardiac MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BMD-lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD-femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD-whole body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain scores on day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGCMS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak passive force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psych- and AC-related hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in daily steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of DCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Modified Rankin Scale score of 0 to 3 at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of high responders with anti-HBs antibody titer > 1000 IU/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma BNP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Charges for ED care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain palliation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: percentage of clopidogrel low-response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Number of GERs detected by pH monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ambulation distance after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in insomnia symptoms
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reduction in wake time after sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in deformity angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPI 24-h Average Pain rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diurnal IOP fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with high diurnal IOP fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posttest scores of knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Insulin Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Muscle force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of laboratory hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of hypocalcemic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean gastric and duodenal erosion scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of gastric ulcers and/or large numbers of gastric erosions
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in mechanical punctuate hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Poor sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: effective bleeding control at 12 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained bleeding control 24‐48 h after the first dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of antibodies against vatreptacog alfa
Endpoint domain: Adverse events/effects
Primary endpoint: Bone mineral density changes at lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Bone mineral density changes at femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: startle potentiation by darkness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baseline startle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postlumbar puncture headache incidence
Endpoint domain: Adverse events/effects
Primary endpoint: skinfold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean medial distance between the parotid glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean shrinkage of parotid glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shear bond strength of porcelain laminate veneers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal activation in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anti-cyclic citrullinated peptide (anti-CCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of severe reactions to hazelnut
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Granulocyte colony forming units (CFU-G)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Granulocyte-macrophage colony forming units (CFU-GM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes